darolutamide


( Last Updated : June 17, 2022)
Generic Name:
darolutamide
Project Status:
Received
Therapeutic Area:
Metastatic castration-sensitive prostate cancer
Manufacturer:
Bayer Inc.
Call for patient/clinician input open:
Brand Name:
Nubeqa
Project Line:
Reimbursement Review
Project Number:
PC0294-000
Call for patient/clinician input closed:
Tumour Type:
Genitourinary
NOC Status at Filing:
Pre NOC

Details


Manufacturer Requested Reimbursement Criteria1:
In combination with docetaxel for the treatment of metastatic castration-sensitive prostate cancer (mCSPC) in patients who are chemotherapy-eligible.
Submission Type:
Initial
Fee Schedule:
Pending
Tumour Type:
Genitourinary
Indications:
For the treatment of patients with metastatic castration sensitive prostate cancer (mCSPC) in combination with docetaxel.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open17-May-22
Call for patient/clinician input closed11-Jul-22
Submission received16-Jun-22
Submission accepted